LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to pr...
Main Authors: | Takahiro Yamazaki, Erik Wennerberg, Michal Hensler, Aitziber Buqué, Jeffrey Kraynak, Jitka Fucikova, Xi Kathy Zhou, Baldur Sveinbjørnsson, Øystein Rekdal, Sandra Demaria, Lorenzo Galluzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2021.1962592 |
Similar Items
-
Immunological barriers to immunotherapy in primary and metastatic breast cancer
by: Mara De Martino, et al.
Published: (2021-08-01) -
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents
by: Giulia Petroni, et al.
Published: (2021-01-01) -
LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
by: Dagmar Zweytick
Published: (2019-11-01) -
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
by: Hsin-Wei Liao, et al.
Published: (2019-10-01) -
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
by: Ketil A. Camilio, et al.
Published: (2019-01-01)